Bristol Myers Squibb (NYSE:BMY) and SystImmune reported data from an early-stage study testing their bispecific antibody-drug conjugate, iza-bren, as a treatment for advanced non-small cell lung cancer and other solid tumors.
Iza-bren is developed collaboratively by SystImmune and Bristol Myers